API XML

Aop: 214

AOP Title

?


Network of SSRIs (selective serotonin reuptake inhibitors)

Short name:

?

Network of SSRIs

Graphical Representation

?

Click to download graphical representation template

Authors

?


Point of Contact

?


Lyle Burgoon   (email point of contact)

Contributors

?


  • Hsin-Yen Wu
  • Lyle Burgoon
  • Edward Perkins

Status

?

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite Under Development


This AOP was last modified on July 24, 2017 15:36

?

Revision dates for related pages

Page Revision Date/Time
Inhibit, serotonin transporter activity April 13, 2017 14:16
Decreased, serotonin transporter activity May 31, 2017 16:47
Decreased, extracellular sodium (Na+) April 13, 2017 14:18
Decreased, extracellular chloride (Cl-) April 13, 2017 14:19
Increased, extracellular serotonin May 31, 2017 16:48
Increased, intracellular sodium (Na+) April 13, 2017 14:21
Increased, intracellular chloride (Cl-) April 13, 2017 14:21
Decreased, intracellular serotonin May 31, 2017 16:47
Decreased, packaged serotonin May 31, 2017 16:46
Decreased, synaptic release May 31, 2017 16:46
Increased, 5-HT3 (5-hydroxytryptamine) June 01, 2017 14:48
Inactivated, 5-HTR (serotonin receptors) May 31, 2017 16:45
Reduce expression, BDNF (Brain-derived neurotrophic factor) May 31, 2017 16:40
Decreased, neuroplasticity May 31, 2017 16:45
Increase, cortisone April 13, 2017 15:14
Activation, Glucocorticoid Receptor September 16, 2017 10:14
Reduced, BDNF (Brain-derived neurotrophic factor) May 31, 2017 17:30
Activation, 5-HT2A (Serotonin 2A) April 13, 2017 15:25
Activate, PLC (Phospholipase C) April 13, 2017 15:26
Increase, inositol triphosphate April 13, 2017 15:27
Increase, intracellular calcium April 13, 2017 15:27
Activate, calmodulin April 13, 2017 15:28
Increase, myosin light chain phosphorylation April 13, 2017 15:29
Increase, vascular smooth muscle contraction April 13, 2017 15:30
Increased, seizure June 01, 2017 11:55
Increased, agitation June 01, 2017 11:35
Increased, depression June 01, 2017 16:06
Increase, hypertension April 13, 2017 15:30
Decreased, extracellular serotonin May 31, 2017 16:46
Decreased, serotonin transporter activity leads to Increased, intracellular sodium (Na+) April 14, 2017 14:44
Decreased, serotonin transporter activity leads to Increased, intracellular chloride (Cl-) April 14, 2017 14:45
Decreased, serotonin transporter activity leads to Decreased, extracellular Na+ April 14, 2017 14:45
Decreased, serotonin transporter activity leads to Decreased, extracellular chloride (Cl-) April 14, 2017 14:46
Decreased, serotonin transporter activity leads to Increased, extracellular serotonin April 14, 2017 14:46
Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin April 14, 2017 14:47
Decreased, intracellular serotonin leads to Decreased, packaged serotonin April 14, 2017 14:47
Decreased, packaged serotonin leads to Decreased, synaptic release April 14, 2017 14:47
Decreased, synaptic release leads to Decreased, extracellular serotonin April 14, 2017 14:48
Decreased, extracellular serotonin leads to Increased, 5-HT3 April 14, 2017 14:49
Decreased, extracellular serotonin leads to Inactivated, 5-HTR April 14, 2017 14:49
Decreased, extracellular serotonin leads to Activation, 5-HT2A April 14, 2017 14:49
Activation, 5-HT2A leads to Activate, PLC April 14, 2017 14:50
Activate, PLC leads to Increase, inositol triphosphate April 14, 2017 14:50
Increase, inositol triphosphate leads to Increase, intracellular calcium April 14, 2017 14:50
Increase, intracellular calcium leads to Activate, calmodulin April 14, 2017 14:51
Activate, calmodulin leads to Increase, myosin light chain phosphorylation April 14, 2017 14:51
Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction April 14, 2017 14:51
Increase, vascular smooth muscle contraction leads to Increase, hypertension April 14, 2017 14:52
Increased, 5-HT3 leads to Increased, seizure April 14, 2017 14:52
Inactivated, 5-HTR leads to Reduce expression, BDNF April 14, 2017 14:53
Reduce expression, BDNF leads to Decreased, neuroplasticity April 14, 2017 14:53
Decreased, neuroplasticity leads to Increased, agitation April 14, 2017 14:54
Decreased, neuroplasticity leads to Increased, depression April 14, 2017 14:54
Increase, cortisone leads to Activation, Glucocorticoid Receptor April 14, 2017 14:55
Activation, Glucocorticoid Receptor leads to Reduced, BDNF April 14, 2017 14:55
SSRI (Selective serotonin reuptake inhibitor) April 13, 2017 15:32
Increase cortisone levels (induced by stress) June 01, 2017 11:16

Abstract

?



Background (optional)

?



Summary of the AOP

?


Events: Molecular Initiating Events (MIE)

?

Key Events (KE)

?

Adverse Outcomes (AO)

?

Sequence Type Event ID Title Short name
1 KE 1316 Inhibit, serotonin transporter activity Inhibit, serotonin transporter activity
2 KE 1317 Decreased, serotonin transporter activity Decreased, serotonin transporter activity
3 KE 1318 Decreased, extracellular sodium (Na+) Decreased, extracellular Na+
4 KE 1319 Decreased, extracellular chloride (Cl-) Decreased, extracellular chloride (Cl-)
5 KE 1320 Increased, extracellular serotonin Increased, extracellular serotonin
6 KE 1347 Decreased, extracellular serotonin Decreased, extracellular serotonin
7 KE 1321 Increased, intracellular sodium (Na+) Increased, intracellular sodium (Na+)
8 KE 1322 Increased, intracellular chloride (Cl-) Increased, intracellular chloride (Cl-)
9 KE 1323 Decreased, intracellular serotonin Decreased, intracellular serotonin
10 KE 1324 Decreased, packaged serotonin Decreased, packaged serotonin
11 KE 1325 Decreased, synaptic release Decreased, synaptic release
12 KE 1326 Increased, 5-HT3 (5-hydroxytryptamine) Increased, 5-HT3
13 KE 1328 Inactivated, 5-HTR (serotonin receptors) Inactivated, 5-HTR
14 KE 1329 Reduce expression, BDNF (Brain-derived neurotrophic factor) Reduce expression, BDNF
15 KE 1330 Decreased, neuroplasticity Decreased, neuroplasticity
16 KE 1334 Increase, cortisone Increase, cortisone
17 KE 122 Activation, Glucocorticoid Receptor Activation, Glucocorticoid Receptor
18 KE 1335 Reduced, BDNF (Brain-derived neurotrophic factor) Reduced, BDNF
19 KE 1336 Activation, 5-HT2A (Serotonin 2A) Activation, 5-HT2A
20 KE 1337 Activate, PLC (Phospholipase C) Activate, PLC
21 KE 1338 Increase, inositol triphosphate Increase, inositol triphosphate
22 KE 1339 Increase, intracellular calcium Increase, intracellular calcium
23 KE 1340 Activate, calmodulin Activate, calmodulin
24 KE 1341 Increase, myosin light chain phosphorylation Increase, myosin light chain phosphorylation
25 KE 1342 Increase, vascular smooth muscle contraction Increase, vascular smooth muscle contraction
26 AO 1344 Increased, seizure Increased, seizure
27 AO 1345 Increased, agitation Increased, agitation
28 AO 1346 Increased, depression Increased, depression
29 AO 1343 Increase, hypertension Increase, hypertension

Relationships Between Two Key Events
(Including MIEs and AOs)

?

Title Adjacency Evidence Quantitative Understanding
Decreased, serotonin transporter activity leads to Increased, intracellular sodium (Na+) adjacent
Decreased, serotonin transporter activity leads to Increased, intracellular chloride (Cl-) adjacent
Decreased, serotonin transporter activity leads to Decreased, extracellular Na+ adjacent
Decreased, serotonin transporter activity leads to Decreased, extracellular chloride (Cl-) adjacent
Decreased, serotonin transporter activity leads to Increased, extracellular serotonin adjacent
Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin adjacent
Decreased, intracellular serotonin leads to Decreased, packaged serotonin adjacent
Decreased, packaged serotonin leads to Decreased, synaptic release adjacent
Decreased, synaptic release leads to Decreased, extracellular serotonin adjacent
Decreased, extracellular serotonin leads to Increased, 5-HT3 adjacent
Decreased, extracellular serotonin leads to Inactivated, 5-HTR adjacent
Decreased, extracellular serotonin leads to Activation, 5-HT2A adjacent
Activation, 5-HT2A leads to Activate, PLC adjacent
Activate, PLC leads to Increase, inositol triphosphate adjacent
Increase, inositol triphosphate leads to Increase, intracellular calcium adjacent
Increase, intracellular calcium leads to Activate, calmodulin adjacent
Activate, calmodulin leads to Increase, myosin light chain phosphorylation adjacent
Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction adjacent
Increase, vascular smooth muscle contraction leads to Increase, hypertension adjacent
Increased, 5-HT3 leads to Increased, seizure adjacent
Inactivated, 5-HTR leads to Reduce expression, BDNF adjacent
Reduce expression, BDNF leads to Decreased, neuroplasticity adjacent
Decreased, neuroplasticity leads to Increased, agitation adjacent
Decreased, neuroplasticity leads to Increased, depression adjacent
Increase, cortisone leads to Activation, Glucocorticoid Receptor adjacent
Activation, Glucocorticoid Receptor leads to Reduced, BDNF adjacent

Network View

?

 

Stressors

?

Life Stage Applicability

?

Taxonomic Applicability

?

Sex Applicability

?

Overall Assessment of the AOP

?



Domain of Applicability

?


Essentiality of the Key Events

?


Evidence Assessment

?


Quantitative Understanding

?


Considerations for Potential Applications of the AOP (optional)

?



References

?